BCL2A1 and neoplasm: Major barriers to the effective treatment of PDAC include the limited efficacy of chemotherapy and the paucity of targetable molecular alterations.2 Activation of GRs on tumor cells results in increased expression of tumor survival genes such as SGK1 and DUSP1, thereby decreasing the efficacy of chemotherapy.4-8 This has led to the development of treatments aimed at the modulation of GR signaling (ie, SGRMs), to enhance the efficacy of cytotoxic agents.5,6